In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Accolade (ACCD – Research Report) and Gilead ...

Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDAInitiated ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

Shares of Gilead Sciences Inc. GILD inched 0.33% higher to $84.95 Friday, on what proved to be an all-around great trading ...

We recently made a list of Goldman Sachs’ List Of Stocks Popular With Mutual Fund Managers: Top 20 Stocks. In this piece, we ...

The deal, first announced last November, would have resulted in the world's biggest pharma company but was ... everyone has been watching Gilead closely to see how it will try to sustain its ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pfizer and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG are racing to produce the first antiviral pill that people could take at early signs of the ...